• Cumberland Pharmaceuticals plans a rolling NDA submission for ifetroban in DMD cardiomyopathy; FDA has granted rolling review.
• High-dose ifetroban delivered a 5.4-percentage-point LVEF benefit versus placebo plus natural-history controls at 12 months (p=0.002).
• No treatment-related serious adverse events or new safety concerns emerged through 36 months.
• Commercial asset divestiture generated approximately $100 million-plus in net proceeds; the debt-free company can fund clinical development, including the planned NDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.